questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Oxidoreductases
Alcohol oxidoreductases
NAD (+) and NADP (+) dependent Alcohol oxidoreductases
3-Hydroxyacyl-CoA dehydrogenases
Hydroxymethylglutaryl-CoA reductases
Hydroxymethylglutaryl-CoA reductases : Questions médicales fréquentes
Diagnostic
5
Dyslipidémie
Cholestérol
Enzymes hépatiques
Échographie
Fonction hépatique
Tests de laboratoire
Tests génétiques
Mutations
Dyslipidémie
Cholestérol
Maladies cardiovasculaires
Dyslipidémie
Tests enzymatiques
Hydroxyméthylglutaryl-CoA
Dyslipidémie
Symptômes
5
Hypercholestérolémie
Douleurs thoraciques
Fatigue
Maladies cardiovasculaires
Cholestérol
Dépôts lipidiques
Xanthomes
Lipides
Dyslipidémie
Asymptomatique
Cholestérol
Dyslipidémie
Troubles de la vision
Douleurs abdominales
Dyslipidémie
Prévention
5
Prévention
Alimentation équilibrée
Exercice physique
Tabagisme
Dyslipidémie
Maladies cardiovasculaires
Alcool
Cholestérol
Dyslipidémie
Contrôles médicaux
Cholestérol
Dyslipidémie
Alimentation
Fibres
Santé
Traitements
5
Statines
Cholestérol
Dyslipidémie
Changements de mode de vie
Alimentation
Exercice physique
Statines
Hydroxyméthylglutaryl-CoA
Cholestérol
Suivi médical
Cholestérol
Dyslipidémie
Effets secondaires
Douleurs musculaires
Troubles digestifs
Complications
5
Maladies cardiaques
AVC
Athérosclérose
Athérosclérose
Cholestérol
Dyslipidémie
Maladies hépatiques
Stéatose
Dyslipidémie
Risques cardiovasculaires
Crises cardiaques
AVC
Réversibilité
Traitement
Changements de mode de vie
Facteurs de risque
5
Obésité
Tabagisme
Inactivité physique
Hérédité
Antécédents familiaux
Dyslipidémie
Stress
Cholestérol
Dyslipidémie
Âge
Dyslipidémie
Facteurs de risque
Diabète
Maladies chroniques
Dyslipidémie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases : Questions médicales les plus fréquentes",
"headline": "Hydroxymethylglutaryl-CoA reductases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hydroxymethylglutaryl-CoA reductases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-29",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"url": "https://questionsmedicales.fr/mesh/D015094",
"about": {
"@type": "MedicalCondition",
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"code": {
"@type": "MedicalCode",
"code": "D015094",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"alternateName": "Hydroxymethylglutaryl-CoA Reductases, NAD-Dependent",
"url": "https://questionsmedicales.fr/mesh/D025781",
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"code": {
"@type": "MedicalCode",
"code": "D025781",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150.415.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"alternateName": "Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent",
"url": "https://questionsmedicales.fr/mesh/D025782",
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"code": {
"@type": "MedicalCode",
"code": "D025782",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150.415.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases",
"alternateName": "Hydroxymethylglutaryl CoA Reductases",
"code": {
"@type": "MedicalCode",
"code": "D006903",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Russell A DeBose-Boyd",
"url": "https://questionsmedicales.fr/author/Russell%20A%20DeBose-Boyd",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "Youngah Jo",
"url": "https://questionsmedicales.fr/author/Youngah%20Jo",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "George Davey Smith",
"url": "https://questionsmedicales.fr/author/George%20Davey%20Smith",
"affiliation": {
"@type": "Organization",
"name": "Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom."
}
},
{
"@type": "Person",
"name": "Hiromasa Yoshioka",
"url": "https://questionsmedicales.fr/author/Hiromasa%20Yoshioka",
"affiliation": {
"@type": "Organization",
"name": "Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan."
}
},
{
"@type": "Person",
"name": "Kenji Ohgane",
"url": "https://questionsmedicales.fr/author/Kenji%20Ohgane",
"affiliation": {
"@type": "Organization",
"name": "Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan. Electronic address: ohgane@rs.tus.ac.jp."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.",
"datePublished": "2023-07-27",
"url": "https://questionsmedicales.fr/article/37541087",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bbrc.2023.07.056"
}
},
{
"@type": "ScholarlyArticle",
"name": "HMG-CoA reductase is a potential therapeutic target for migraine: a mendelian randomization study.",
"datePublished": "2024-05-27",
"url": "https://questionsmedicales.fr/article/38802400",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-61628-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Regulated degradation of HMG CoA reductase requires conformational changes in sterol-sensing domain.",
"datePublished": "2022-07-25",
"url": "https://questionsmedicales.fr/article/35879350",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-022-32025-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "A fungal tolerance trait and selective inhibitors proffer HMG-CoA reductase as a herbicide mode-of-action.",
"datePublished": "2022-09-22",
"url": "https://questionsmedicales.fr/article/36137996",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-022-33185-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinical associations of patients with anti-3-hydroxy-3-methylglutaryl CoA reductase antibody-associated immune-mediated necrotising myopathy.",
"datePublished": "2023-01-27",
"url": "https://questionsmedicales.fr/article/36625419",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/imj.16004"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D000429"
},
{
"@type": "ListItem",
"position": 6,
"name": "NAD (+) and NADP (+) dependent Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D064430"
},
{
"@type": "ListItem",
"position": 7,
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"item": "https://questionsmedicales.fr/mesh/D015094"
},
{
"@type": "ListItem",
"position": 8,
"name": "Hydroxymethylglutaryl-CoA reductases",
"item": "https://questionsmedicales.fr/mesh/D006903"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hydroxymethylglutaryl-CoA reductases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hydroxymethylglutaryl-CoA reductases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-29",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hydroxymethylglutaryl-CoA reductases",
"description": "Comment diagnostiquer une dysfonction des réductases ?\nQuels examens sont recommandés pour évaluer les réductases ?\nLes tests génétiques sont-ils utiles ?\nQuels symptômes indiquent un problème avec les réductases ?\nComment évaluer l'activité des réductases ?",
"url": "https://questionsmedicales.fr/mesh/D006903#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels sont les symptômes d'une hypercholestérolémie ?\nComment se manifeste une maladie liée aux réductases ?\nY a-t-il des signes cutanés associés ?\nLes symptômes sont-ils toujours présents ?\nQuels autres symptômes peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D006903#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hydroxymethylglutaryl-CoA reductases",
"description": "Comment prévenir les problèmes liés aux réductases ?\nLe tabagisme influence-t-il les réductases ?\nL'alcool a-t-il un impact sur le cholestérol ?\nLes contrôles médicaux réguliers sont-ils importants ?\nQuels aliments privilégier pour la santé des réductases ?",
"url": "https://questionsmedicales.fr/mesh/D006903#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels médicaments sont utilisés pour traiter les dysfonctionnements ?\nY a-t-il des traitements non médicamenteux ?\nComment les statines agissent-elles ?\nLes traitements sont-ils efficaces à long terme ?\nQuels effets secondaires peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D006903#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quelles complications peuvent survenir avec une dyslipidémie ?\nComment l'athérosclérose est-elle liée aux réductases ?\nLes maladies hépatiques sont-elles une complication ?\nQuels risques cardiovasculaires sont associés ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D006903#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels sont les principaux facteurs de risque ?\nL'hérédité joue-t-elle un rôle ?\nLe stress influence-t-il les niveaux de cholestérol ?\nL'âge est-il un facteur de risque ?\nLes maladies chroniques influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006903#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des réductases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de cholestérol et des enzymes hépatiques sont effectués."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour évaluer les réductases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une échographie abdominale et des tests de fonction hépatique peuvent être recommandés."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations génétiques affectant les réductases."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème avec les réductases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de cholestérol et des maladies cardiovasculaires peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'activité des réductases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques spécifiques peuvent mesurer l'activité des hydroxyméthylglutaryl-CoA réductases."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une hypercholestérolémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs thoraciques, fatigue et problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une maladie liée aux réductases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par des dépôts de cholestérol dans les artères et des douleurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des xanthomes peuvent apparaître, indiquant une accumulation de lipides."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré des niveaux élevés de cholestérol."
}
},
{
"@type": "Question",
"name": "Quels autres symptômes peuvent survenir ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la vision et des douleurs abdominales peuvent également se manifester."
}
},
{
"@type": "Question",
"name": "Comment prévenir les problèmes liés aux réductases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice régulier aident à maintenir un bon cholestérol."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les réductases ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de dyslipidémie et de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'alcool a-t-il un impact sur le cholestérol ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une consommation excessive d'alcool peut aggraver les niveaux de cholestérol."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de détecter précocement les anomalies du cholestérol."
}
},
{
"@type": "Question",
"name": "Quels aliments privilégier pour la santé des réductases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les aliments riches en fibres, comme les fruits et légumes, sont bénéfiques."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter les dysfonctionnements ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les statines sont couramment prescrites pour réduire le cholestérol sanguin."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements de mode de vie comme l'alimentation et l'exercice sont recommandés."
}
},
{
"@type": "Question",
"name": "Comment les statines agissent-elles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles inhibent l'hydroxyméthylglutaryl-CoA réductase, réduisant ainsi la production de cholestérol."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avec un suivi régulier, les traitements peuvent maintenir des niveaux de cholestérol sains."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs musculaires et des troubles digestifs sont des effets secondaires possibles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dyslipidémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent les maladies cardiaques, les AVC et l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Comment l'athérosclérose est-elle liée aux réductases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une production excessive de cholestérol due à des réductases dysfonctionnelles peut provoquer l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques sont-elles une complication ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une accumulation de lipides peut entraîner des maladies hépatiques comme la stéatose."
}
},
{
"@type": "Question",
"name": "Quels risques cardiovasculaires sont associés ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux élevés de cholestérol augmentent le risque de crises cardiaques et d'AVC."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et des changements de mode de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, le tabagisme, l'inactivité physique et une mauvaise alimentation."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de dyslipidémie augmentent le risque de problèmes liés aux réductases."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il les niveaux de cholestérol ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à des niveaux de cholestérol élevés."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de dyslipidémie augmente avec l'âge, surtout après 45 ans."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le diabète augmentent le risque de dyslipidémie et de complications."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 26/03/2025
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA.
4 publications dans cette catégorie
Affiliations :
Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
3 publications dans cette catégorie
Affiliations :
Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
3 publications dans cette catégorie
Affiliations :
Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
3 publications dans cette catégorie
Affiliations :
Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan. Electronic address: ohgane@rs.tus.ac.jp.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Louisiana State University; Baton Rouge, LA 70803, USA. Electronic address: mtkalc1@lsu.edu.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Louisiana State University; Baton Rouge, LA 70803, USA. Electronic address: gwaldro@lsu.edu.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Kunming Institute of Botany Chinese Academy of Sciences, State Key Laboratory of Phytochemistry and Plant Resources in West China, CHINA.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
National Institute for Health and Welfare, Helsinki, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom.
Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
National Institute for Health Research, Oxford Biomedical Research Centre, Oxford University Hospital, Oxford, United Kingdom.
Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Homerton College, University of Cambridge, Cambridge, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Institute of Cardiovascular Science, University College London, London, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Institute of Cardiovascular Science, University College London, London, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Chemistry, Fimlab Laboratories, Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technologies, University of Tampere, Tampere, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, University of Turku, Turku, Finland.
Division of Medicine, Turku University Hospital, Turku, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
Statins are cholesterol-lowering drugs that have exhibited potential as cancer therapeutic agents. However, as some cancer cells are resistant to statins, broadening an anticancer spectrum of statins ...
Statins are thought to have positive effects on migraine but existing data are inconclusive. We aimed to evaluate the causal effect of such drugs on migraines using Mendelian randomization. We used fo...
3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is the rate-limiting enzyme in cholesterol synthesis and target of cholesterol-lowering statin drugs. Accumulation of sterols in endoplasmic ret...
Decades of intense herbicide use has led to resistance in weeds. Without innovative weed management practices and new herbicidal modes of action, the unabated rise of herbicide resistance will undoubt...
Anti-3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) antibodies are associated with a subtype of immune-mediated necrotising myopathy (IMNM)....
To determine clinical associations of anti-HMGCR antibodies for anti-HMGCR-associated IMNM (HMGCR-IMNM) among a cohort of patients in Western Australia and to determine whether serial HMGCR antibody l...
Adult patients with positive anti-HMGCR antibodies detected by enzyme-linked immunosorbent assay between January 2015 and November 2019 were included. Symptoms, examination findings, imaging findings ...
Among 26 patients with positive anti-HMGCR antibodies, 23 were diagnosed with HMGCR-IMNM representing a positive predictive value (PPV) of 88%. Myopathy was frequently severe at diagnosis with limb we...
The PPV of anti-HMGCR antibodies for HMGCR-IMNM in this Western Australian cohort is 88%. Patients typically present with proximal limb weakness, dysphagia and markedly elevated CK, and, despite multi...
It is unclear whether hydroxymethylglutaryl-CoA reductase inhibitor (statin) therapy decreases the risk of mortality and cardiovascular disease (CVD) in patients undergoing peritoneal dialysis (PD)....
We performed a literature search of PubMed, Cochrane Library, Embase, and other databases for research publications up to June 2022. The outcomes of interest were fatal and nonfatal CVDs, all-cause mo...
Nine studies, including 2,933 patients undergoing PD, were included. Among them, three studies, including 2,099 patients, reported all-cause mortality, and three, including 1,571 patients, reported CV...
Although statin therapy was associated with significantly reduced low-density lipoprotein cholesterol, total cholesterol, and C-reactive protein levels, the probable beneficial effect of statins on CV...
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGCR), and exert adverse effects on mitochondrial function, although the mechanisms underlying these e...
We established a new mouse strain using the Cre/loxP system, which enabled whole-body deletion of Hmgcr expression. These mice were crossed with Rosa26...
Lack of Hmgcr expression resulted in lethality, due to acute liver damage caused by rapid disruption of mitochondrial fatty acid β-oxidation and very high accumulation of long-chain (LC) acylcarnitine...
Our findings suggest that HMGCR is crucial for maintaining energy metabolism balance, and its activity is necessary for functional mitochondrial β-oxidation. Moreover, statin-induced adverse reactions...
As blood cholesterol increases, it accumulates in the intima of blood vessels, elevating the risk of atherosclerosis and coronary artery disease. Drugs that inhibit enzymes essential for cholesterol s...
Mitochondrial 3-hydroxymethylglutaryl-CoA synthase-2 (HMGCS2) is the main enzyme involved in ketogenesis. It is an essential enzyme for the catalysis of β-oxidation-derived-acetyl-CoA and acetoacetyl ...
Two new fungal polyketides with unusual skeleton, collecapsins A and B (...